Dinaciclib (SCH 727965) Is a Novel Cyclin-Dependent Kinase (CDK) Inhibitor That Exhibits Activity In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia (CLL)
Flynn JMM, Andritsos LA, Jones JA et al.
Key Points:
Dose-finding phase I trial of Dinaciclib for patients with relapsed/refractroy CLL.
In 52 enrolled patients one episode of dose-limiting toxicity (DLT) noted at 7mg/m2 (sepsis/death) and two at dose level of 17mg/m2 (hyperacute tumor lysis syndrome and pneumonia).
Suggested recommended phase II dose 14mg/m2.
Overall response rate 58%, while 57% patients had del 17p and achieved at least partial response.
Implications:
- Recommended phase II dose of Dinaciclib 14mg/m2 and active relapsed/refractory setting even in patients harboring del 17p.
View the original abstract on the ASH website.
